SCM
CBIO icon

Stonepine Capital Management’s Crescent Biopharma CBIO Stock Holding History

Stonepine Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$720K Sell
40,000
-45,000
-53% -$879K 0.41% 56
2026
Q1 		$1.56M Sell
85,000
-2,682
-3% -$30.8K 0.63% 27
2025
Q4 		$1.04M Buy
+87,682
New +$1.12M 0.76% 37

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stonepine Capital Management's CBIO Position: Q2 2026 in Review

Stonepine Capital Management reduced its Crescent Biopharma (CBIO) stake by 53% in Q2 2026, selling an estimated $879K and leaving 40,000 shares worth $720K. The position accounts for 0.41% of the portfolio, ranked #56.

Stonepine Capital Management first reported a position in CBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.56M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Stonepine Capital Management held 40,000 shares of Crescent Biopharma worth $720K as of Q2 2026.
  • Stonepine Capital Management sold 45,000 Crescent Biopharma shares in Q2 2026, an estimated $879K.
  • Crescent Biopharma made up 0.41% of Stonepine Capital Management's portfolio in Q2 2026, its #56 holding.
  • Stonepine Capital Management first reported a position in Crescent Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's Crescent Biopharma position peaked at $1.56M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.